Gilead Sciences Announces Third Quarter 2026 Financial Results
Gilead reported Q3 2026 total revenues of $8.30 billion (+7% YoY), with product sales ex-Veklury up 16% to $8.2 billion — its strongest base-business growth in over a decade. HIV sales rose 18% to $6.25 billion, with Descovy up 49% and Yeztugo scaling to $305 million; Trodelvy grew 42% to $506 million, while Veklury (-69%) and Cell Therapy (-18%) declined. GAAP diluted EPS was $1.94 and non-GAAP EPS $2.55. FY26 product sales guidance was raised to $31.0B-$31.3B from $30.1B-$30.4B, the second raise of the year totaling $1.6 billion since the start of 2026.
Key figures
- Eps
- 1.94
- Revenue
- 8300000000
- Guidance
- FY26 product sales $31.0B-$31.3B (raised from $30.1B-$30.4B); product sales ex-Veklury $30.7B-$31.0B; GAAP diluted loss per share $(4.40)-$(4.05); non-GAAP diluted loss per share $(1.20)-$(0.85)
- Revenue Yoy
- 7%
- Hiv sales
- 6249000000
- Non gaap eps
- 2.55
- Descovy sales
- 1046000000
- Hiv sales yoy
- 18%
- Veklury sales
- 86000000
- Biktarvy sales
- 4100000000
- Free cash flow
- 4798000000
- Trodelvy sales
- 506000000
- Iprd charges ytd
- 12400000000
- Descovy sales yoy
- 49%
- Veklury sales yoy
- -69%
- Biktarvy sales yoy
- 10%
- Cell therapy sales
- 355000000
- Dividend per share
- 0.82
- Trodelvy sales yoy
- 42%
- Operating cash flow
- 5035000000
- Product gross margin
- 81.0%
- Cell therapy sales yoy
- -18%
- Product sales ex veklury
- 8203000000
- Product sales ex veklury yoy
- 16%
- Non gaap product gross margin
- 88.1%
- Cash and marketable securities
- 6437000000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.